
Innoviva’s ZEVTERA® & XACDURO® Nominated for 2025 Prix Galien USA Award
Innoviva Specialty Therapeutics Earns Dual Nominations for 2025 Prix Galien USA Best Pharmaceutical Product Award for ZEVTERA® and XACDURO® Innoviva Specialty Therapeutics, a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced that two of its flagship infectious disease therapies…












